BIVF, Gründerfonds Ruhr lead €12m series-A round for Abalos

NRW Bank, the state development bank for North Rhine-Westphalia, and venture capital investor High-Tech Gründerfonds also participated in the round.

Representatives from all investors will join the company's newly formed board of directors. Abalos has also announced Marcus Kostka as CEO and Jörg Vollmer as chief scientific officer.

The fresh capital will go towards advancing Abalos's lead candidates towards clinical testing.

Company
Abalos is dedicated to developing immuno-oncology therapeutics based on a specific arenavirus strain that preferentially infects and proliferates in cancer cells generating a strong anti-tumour immune response. Based in Essen, the company was founded in 2019.

People
High-Tech Gründerfonds – Frank Hensel (principal).
Gründerfonds Ruhr – Aristotelis Nastos (managing director).
Abalos Therapeutics – Marcus Kostka (CEO); Jörg Vollmer (chief scientific officer).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• High-Tech Gründerfonds
• Germany
• healthcare
• Venture